{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:52:15Z","timestamp":1792637535026,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T00:00:00Z","timestamp":1284595200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s10096-010-1058-0","type":"journal-article","created":{"date-parts":[[2010,9,15]],"date-time":"2010-09-15T05:47:46Z","timestamp":1284529666000},"page":"89-95","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin"],"prefix":"10.1007","volume":"30","author":[{"given":"M. E.","family":"Pach\u00f3n-Ib\u00e1\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ribes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. \u00c1.","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tubau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gudiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cabellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,16]]},"reference":[{"issue":"Suppl 4","key":"1058_CR1","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1086\/314078","volume":"31","author":"AW Karchmer","year":"2000","unstructured":"Karchmer AW (2000) Nosocomial bloodstream infections: organisms, risk factors, and implications. Clin Infect Dis 31(Suppl 4):S139\u2013S143","journal-title":"Clin Infect Dis"},{"key":"1058_CR2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejim.2008.08.016","volume":"20","author":"M Falcone","year":"2009","unstructured":"Falcone M, Serra P, Venditti M (2009) Serious infections due to methicillin-resistant Staphylococcus aureus: an evolving challenge for physicians. Eur J Intern Med 20:343\u2013347","journal-title":"Eur J Intern Med"},{"key":"1058_CR3","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/jac\/43.6.846","volume":"43","author":"R Geisel","year":"1999","unstructured":"Geisel R, Schmitz FJ, Thomas L, Berns G, Zetsche O, Ulrich B, Fluit AC, Labischinsky H, Witte W (1999) Emergence of heterogeneous intermediate vancomycin resistance in Staphylococcus aureus isolates in the D\u00fcsseldorf area. J Antimicrob Chemother 43:846\u2013848","journal-title":"J Antimicrob Chemother"},{"key":"1058_CR4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","volume":"40","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135\u2013136","journal-title":"J Antimicrob Chemother"},{"key":"1058_CR5","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1128\/JCM.38.10.3879-3881.2000","volume":"38","author":"MN Kim","year":"2000","unstructured":"Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K (2000) Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 38:3879\u20133881","journal-title":"J Clin Microbiol"},{"key":"1058_CR6","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1128\/JCM.01262-06","volume":"45","author":"Y Maor","year":"2007","unstructured":"Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N (2007) Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 45:1511\u20131514","journal-title":"J Clin Microbiol"},{"key":"1058_CR7","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1128\/JCM.41.11.5147-5152.2003","volume":"41","author":"F Bert","year":"2003","unstructured":"Bert F, Clarissou J, Durand F, Delefosse D, Chauvet C, Lefebvre P, Lambert N, Branger C (2003) Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol 41:5147\u20135152","journal-title":"J Clin Microbiol"},{"issue":"Suppl 1","key":"1058_CR8","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1093\/clinids\/24.Supplement_1.S74","volume":"24","author":"GA Ayliffe","year":"1997","unstructured":"Ayliffe GA (1997) The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 24(Suppl 1):S74\u2013S79","journal-title":"Clin Infect Dis"},{"key":"1058_CR9","first-page":"565","volume":"51","author":"Centers for Disease Control and Prevention (CDC)","year":"2002","unstructured":"Centers for Disease Control and Prevention (CDC) (2002) Staphylococcus aureus resistant to vancomycin\u2014United States, 2002. MMWR Morb Mortal Wkly Rep 51:565\u2013567","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1058_CR10","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1073\/pnas.122108599","volume":"99","author":"MC Enright","year":"2002","unstructured":"Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG (2002) The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 99:7687\u20137692","journal-title":"Proc Natl Acad Sci USA"},{"key":"1058_CR11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/jama.286.10.1201","volume":"286","author":"AV Groom","year":"2001","unstructured":"Groom AV, Wolsey DH, Naimi TS, Smith K, Johnson S, Boxrud D, Moore KA, Cheek JE (2001) Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 286:1201\u20131205","journal-title":"JAMA"},{"key":"1058_CR12","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/bmj.324.7350.1365","volume":"324","author":"H Grundmann","year":"2002","unstructured":"Grundmann H, Tami A, Hori S, Halwani M, Slack R (2002) Nottingham Staphylococcus aureus population study: prevalence of MRSA among elderly people in the community. Br Med J 324:1365\u20131366","journal-title":"Br Med J"},{"key":"1058_CR13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/00006454-200108000-00009","volume":"20","author":"FM Hussain","year":"2001","unstructured":"Hussain FM, Boyle-Vavra S, Daum RS (2001) Community-acquired methicillin-resistant Staphylococcus aureus colonization in healthy children attending an outpatient pediatric clinic. Pediatr Infect Dis J 20:763\u2013767","journal-title":"Pediatr Infect Dis J"},{"key":"1058_CR14","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJM199808203390806","volume":"339","author":"FD Lowy","year":"1998","unstructured":"Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339:520\u2013532","journal-title":"N Engl J Med"},{"key":"1058_CR15","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/322693","volume":"33","author":"TS Naimi","year":"2001","unstructured":"Naimi TS, LeDell KH, Boxrud DJ, Groom AV, Steward CD, Johnson SK, Besser JM, O\u2019Boyle C, Danila RN, Cheek JE, Osterholm MT, Moore KA, Smith KE (2001) Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996\u20131998. Clin Infect Dis 33:990\u2013996","journal-title":"Clin Infect Dis"},{"key":"1058_CR16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1592\/phco.27.2.227","volume":"27","author":"RH Drew","year":"2007","unstructured":"Drew RH (2007) Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 27:227\u2013249","journal-title":"Pharmacotherapy"},{"key":"1058_CR17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.00510-07","volume":"52","author":"F Marco","year":"2008","unstructured":"Marco F, de la M\u00e0ria CG, Armero Y, Amat E, Soy D, Moreno A, del R\u00edo A, Almela M, Mestres CA, Gatell JM, Jim\u00e9nez de Anta MT, Mir\u00f3 JM; Hospital Clinic Experimental Endocarditis Study Group (2008) Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 52:2538\u20132543","journal-title":"Antimicrob Agents Chemother"},{"key":"1058_CR18","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1128\/AAC.00208-09","volume":"53","author":"O Murillo","year":"2009","unstructured":"Murillo O, Garrig\u00f3s C, Pach\u00f3n ME, Euba G, Verdaguer R, Cabellos C, Cabo J, Gudiol F, Ariza J (2009) Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53:4252\u20134257","journal-title":"Antimicrob Agents Chemother"},{"key":"1058_CR19","first-page":"15","volume":"16","author":"M Gobernado","year":"2003","unstructured":"Gobernado M (2003) Fosfomycin. Rev Esp Quimioter 16:15\u201340","journal-title":"Rev Esp Quimioter"},{"key":"1058_CR20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","volume":"53","author":"SS Patel","year":"1997","unstructured":"Patel SS, Balfour JA, Bryson HM (1997) Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 53:637\u2013656","journal-title":"Drugs"},{"key":"1058_CR21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0891-5520(20)30278-6","volume":"3","author":"WA Craig","year":"1989","unstructured":"Craig WA, Ebert SC (1989) Protein binding and its significance in antibacterial therapy. Infect Dis Clin North Am 3:407\u2013414","journal-title":"Infect Dis Clin North Am"},{"key":"1058_CR22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkm476","volume":"61","author":"JW Mouton","year":"2008","unstructured":"Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O (2008) Tissue concentrations: do we ever learn? J Antimicrob Chemother 61:235\u2013237","journal-title":"J Antimicrob Chemother"},{"key":"1058_CR23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jac\/40.3.393","volume":"40","author":"P Arca","year":"1997","unstructured":"Arca P, Reguera G, Hardisson C (1997) Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother 40:393\u2013399","journal-title":"J Antimicrob Chemother"},{"key":"1058_CR24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/48.2.209","volume":"48","author":"K Grif","year":"2001","unstructured":"Grif K, Dierich MP, Pfaller K, Miglioli PA, Allerberger F (2001) In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 48:209\u2013217","journal-title":"J Antimicrob Chemother"},{"key":"1058_CR25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s10156-003-0266-2","volume":"9","author":"H Nakazawa","year":"2003","unstructured":"Nakazawa H, Kikuchi Y, Honda T, Isago T, Nozaki M (2003) Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. J Infect Chemother 9:304\u2013309","journal-title":"J Infect Chemother"},{"key":"1058_CR26","first-page":"252","volume":"19","author":"JM Sahuquillo Arce","year":"2006","unstructured":"Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Est\u00e9vez R, Cant\u00f3n E, Gobernado M (2006) In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter 19:252\u2013257","journal-title":"Rev Esp Quimioter"},{"key":"1058_CR27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF01968058","volume":"9","author":"P Chavanet","year":"1990","unstructured":"Chavanet P, Muggeo E, Waldner A, Dijoux S, Caillot D, Portier H (1990) Synergism between cefotaxime and fosfomycin in the therapy of methicillin and gentamicin resistant Staphylococcus aureus infection in rabbits. Eur J Clin Microbiol Infect Dis 9:271\u2013275","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1058_CR28","unstructured":"Marco F, Miro JM, Del Rio A, Garc\u00eda C, Gavald\u00e1 J, Dern E, Almela M, Soy M, Torra M, Moreno A, Pahissa A, Gatell JM, Jim\u00e9nez De Anta MT (2000) Efficacy of Fosfomycin (Fos) plus Imipenem (Imi) or Ceftriaxone (Cro) Combinations in the Treatment of Experimental Endocarditis (EE) due to Methicillin-Resistant Staphylococcus aureus (MRSA). Abstract of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 2000, p. 58"},{"key":"1058_CR29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijantimicag.2004.07.015","volume":"25","author":"K Morikawa","year":"2005","unstructured":"Morikawa K, Nonaka M, Yoshikawa Y, Torii I (2005) Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model. Int J Antimicrob Agents 25:44\u201350","journal-title":"Int J Antimicrob Agents"},{"key":"1058_CR30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.31.9.1444","volume":"31","author":"A Rodr\u00edguez","year":"1987","unstructured":"Rodr\u00edguez A, Vicente MV, Olay T (1987) Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 31:1444\u20131445","journal-title":"Antimicrob Agents Chemother"},{"key":"1058_CR31","unstructured":"Garc\u00eda de la Mar\u00eda C, Marco F, Miro JM, Armero Y, Jim\u00e9nez-Alzate MP, D\u00edaz ME, Moreno A, Almela M, Benito N, Claramonte X, Torra M, Mestres CA, Perez N, Gatell JM, Jim\u00e9nez de Anta MT (2003) Efficacy of Fosfomycin (Fos) plus Imipenem (Imi) or Ceftriaxone (Cro) Combination in the Treatment of Experimental Endocarditis (EE) Due to Methicillin Resistant (MRSA) or Glycopeptide Intermediate Resistant (GISA) Staphylococcus aureus. Abstract of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003, p. 1091"},{"key":"1058_CR32","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1128\/AAC.45.4.1292-1294.2001","volume":"45","author":"N Aritaka","year":"2001","unstructured":"Aritaka N, Hanaki H, Cui L, Hiramatsu K (2001) Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother 45:1292\u20131294","journal-title":"Antimicrob Agents Chemother"},{"key":"1058_CR33","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(99)01017-X","volume":"353","author":"J Ariza","year":"1999","unstructured":"Ariza J, Pujol M, Cabo J, Pe\u00f1a C, Fern\u00e1ndez N, Li\u00f1ares J, Ayats J, Gudiol F (1999) Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587\u20131588","journal-title":"Lancet"},{"key":"1058_CR34","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2003) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A6, 6th edn. CLSI, Wayne, PA"},{"key":"1058_CR35","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1128\/AAC.00523-06","volume":"50","author":"O Murillo","year":"2006","unstructured":"Murillo O, Dom\u00e9nech A, Garcia A, Tubau F, Cabellos C, Gudiol F, Ariza J (2006) Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 50:4011\u20134017","journal-title":"Antimicrob Agents Chemother"},{"key":"1058_CR36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1089\/mdr.2004.10.346","volume":"10","author":"A Dom\u00e9nech","year":"2004","unstructured":"Dom\u00e9nech A, Ribes S, Cabellos C, Dom\u00ednguez MA, Montero A, Li\u00f1ares J, Ariza J, Gudiol F (2004) A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections. Microb Drug Resist 10:346\u2013353","journal-title":"Microb Drug Resist"},{"key":"1058_CR37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3201\/eid0501.990118","volume":"5","author":"SS Rotun","year":"1999","unstructured":"Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM (1999) Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 5:147\u2013149","journal-title":"Emerg Infect Dis"},{"key":"1058_CR38","first-page":"219","volume":"13","author":"C Quentin","year":"1987","unstructured":"Quentin C, Saivin S, Lafferriere C, Noury P, Bebear C (1987) In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: a study by the time\u2013kill curve method. Drugs Exp Clin Res 13:219\u2013224","journal-title":"Drugs Exp Clin Res"},{"key":"1058_CR39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","volume":"32","author":"E Rubinstein","year":"2001","unstructured":"Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32:402\u2013412","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1058-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-010-1058-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1058-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T23:29:17Z","timestamp":1636500557000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-010-1058-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s10096-010-1058-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,16]]}}}